Jul 1, 2026 · 7 min
European markets split as Galderma slumps and CMC Markets surges
Galderma Slumps, AB Foods Falls, CMC Markets Soars
Understanding these sharp market divergences reveals how regulatory decisions and retail health are reshaping the European corporate landscape.
- 1Galderma shares slumped following an unexpected FDA rejection of its new dermatological Botox competitor.
- 2Associated British Foods fell on weak Primark sales and financial losses within its sugar business unit.
- 3CMC Markets saw its stock soar after raising its long-term profit guidance amid strong trading activity.
Don't miss
CMC Markets defies the broader market downturn by raising its long-term profit guidance and sending its stock soaring.
The brief
European markets are facing a sharp divide as regulatory hurdles and retail slumps drag down major players, while financial services firms capitalize on shifting market conditions to post record gains.
Galderma suffered a major setback after the FDA rejected its new Botox competitor, causing its stock to slump and highlighting the high-stakes regulatory risks inherent in the global dermatology market.
Meanwhile, Associated British Foods saw its shares tumble. The multinational conglomerate is grappling with declining sales at its high-street fashion chain Primark alongside mounting losses in its sugar division.
Defying the downward trend, CMC Markets saw its stock surge to record highs. The online trading platform raised its long-term profit guidance, signaling robust health for financial services providers.
What was said on this episode
7 statements · 3 positive · 4 negative
AB Foods shares fell by their largest amount in over two months.
“shares fell this morning by the most in over two months”
Listen at 1:01
AB Foods cut its sugar-business outlook for 2026 and 2027.
“they have cut the outlook for the sugar business for 2026 and 2027”
Listen at 1:36
Galderma shares dropped more than 6% that morning.
“Shares dropped as much as over 6% this morning”
Listen at 2:35
Jefferies expects Galderma approval to be delayed nine to twelve months.
“Jefferies are seeing about a 9 to 12 month delay to approval”
Listen at 3:39
CMC Markets raised its profit guidance for the year.
“They raised their profit guidance for the year”
Listen at 3:53
CMC Markets stock has potential to re-rate after the guidance upgrade.
“their stock has kind of re rating potential on the back of this”
Listen at 4:10
CMC Markets shares gained about 88% over the year.
“it takes gains for the whole year to about 88%”
Listen at 4:20
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
CMC Markets
Food and Drug AdministrationListen to the full episode and explore every guest, topic, and moment on PodLume.